Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The outcome of 24 months of cabergoline treatment on prolactin (PRL) normalization, tumor shrinkage, restoration of pituitary function, and semen alterations was prospectively investigated in 41 men with macro- (age 17-70 yr) and 10 with microprolactinoma (age 18-53 yr). Fifty-one age-matched men served as controls for semen analysis. At study entry, of the 41 patients with macroprolactinoma, 17 (41.4%) had visual field defects, 14 (34.1%) had headache, eight (19.5%) had galactorrhea, 22 (53.6%) had hypopituitarism apart from hypogonadism, and 30 (73.2%) had low testosterone levels; of the 10 patients with microprolactinoma, none had visual field defects, galactorrhea, or hypopituitarism apart from hypogonadism, two had headache (20%), and five had low testosterone levels (50%; P = 0.3). After 24 months of therapy, 1) PRL levels normalized in 31 patients with macro- (75.6%) and in eight with microprolactinoma (80%; P = 0.9), and galactorrhea disappeared in all patients; 2) maximal tumor diameter reduced by 73.7 +/- 22.6% in macro- and 72.8 +/- 28.3% in microprolactinomas (P = 0.91), and 15 macro- (30%) and seven microprolactinomas (46.7%; P = 0.37) disappeared; 3) visual field defects disappeared in 15 (75%) patients with macroprolactinoma, and headache disappeared in 15 (83%) patients with macro- and in one with microprolactinoma (50%); 4) GH secretion recovered in 62.5% and ACTH secretion in 60% of patients; 5) testosterone levels normalized in 25 patients with macro- (60.9%) and six with microprolactinoma (60%) after 6 months, and 20 patients required testosterone or gonadotropin replacement (in 14 or six patients, respectively); and 6) sperm volume and count normalized in all patients who normalized testosterone levels, whereas motility normalized in more than 80%. Cabergoline therapy was well tolerated; only 4.5% of patients had side effects at high doses. These data demonstrate that cabergoline treatment is as effective and safe in men as in women with prolactinoma and can be successfully used as primary therapy even in men bearing large macroprolactinomas.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In case of a pituitary prolactinoma, treatment with dopamine agonists can be indicated and can result in normalization of testosterone levels and improvement of semen quality and libido [1,3,28,29,30].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [30]
In the citing paper
“Further research has reported the recovery of other hormonal axes following adenoma shrinkage (227)”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [227]
Citations
Cites
; (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.2.379 · Cited by 655
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
Verhelst, J., Abs, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velkeniers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5810 · Cited by 449
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
Colao, A., Di Sarno, A., Cappabianca, P., Di Somma, C., Pivonello, R., & Lombardi, G. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022657 · Cited by 336
Self-citationSex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study1
Delgrange, E., Trouillas, J., Maiter, D., Donckier, J., & Tourniaire, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4088 · Cited by 277
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
Colao, A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.876 · Cited by 276
Self-citationColao, A., Sarno, A., Cappabianca, P., Briganti, F., Pivonello, R., Somma, C., Faggiano, A., Biondi, B., & Lombardi, G. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480325 · Cited by 267
Self-citationNew approach to the diagnosis of growth hormone deficiency in adults
Ghigo, E., Aimaretti, G., Gianotti, L., Bellone, J., Arvat, E., & Camanni, F. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1340352 · Cited by 257
Di Sarno, A., Landi, M. L., Cappabianca, P., Di Salle, F., Rossi, F. W., Pivonello, R., Di Somma, C., Faggiano, A., Lombardi, G., & Colao, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8054 · Cited by 247
Self-citationColao, A., Di Sarno, A., Landi, M. L., Scavuzzo, F., Cappabianca, P., Pivonello, R., Volpe, R., Di Salle, F., Cirillo, S., Annunziato, L., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6657 · Cited by 227
Self-citationTreatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline
Biller, B. M. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.6.2338 · Cited by 216
Cited by
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Advances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
Self-citationPetersenn, S., Fleseriu, M., Casanueva, F. F., Giustina, A., Biermasz, N., Biller, B. M. K., Bronstein, M., Chanson, P., Fukuoka, H., Gadelha, M., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00886-5 · Cited by 411
Schneider, H. J., Aimaretti, G., Kreitschmann-Andermahr, I., Stalla, G.-K., & Ghigo, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60673-4 · Cited by 336
Sexual dysfunction in men and women with endocrine disorders
Bhasin, S., Enzlin, P., Coviello, A., & Basson, R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60280-3 · Cited by 319
The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new
Chanson, P., & Maiter, D. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101290 · Cited by 237
Delgrange, E., Daems, T., Verhelst, J., Abs, R., & Maiter, D. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0012 · Cited by 194
Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients
Ono, M., Miki, N., Kawamata, T., Makino, R., Amano, K., Seki, T., Kubo, O., Hori, T., & Takano, K. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2758 · Cited by 191
Kreutzer, J., Buslei, R., Wallaschofski, H., Hofmann, B., Nimsky, C., Fahlbusch, R., & Buchfelder, M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0248 · Cited by 185
Medical treatment of prolactinomas
Colao, A. A. L., & Savastano, S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.37 · Cited by 175
Self-citationTreatment of hyperprolactinemia: a systematic review and meta-analysis
Wang, A. T., Mullan, R. J., Lane, M. A., Hazem, A., Prasad, C., Gathaiya, N. W., Fernández-Balsells, M., Bagatto, A., Yglesias, F. C., Carey, J., et al. (2012) · Systematic Reviews · doi:10.1186/2046-4053-1-33 · Cited by 159
Gamma Knife Radiosurgery for Medically and Surgically Refractory Prolactinomas
Pouratian, N., Sheehan, J. P., Jagannathan, J., Laws, E. R., Steiner, L. E., & Vance, M. L. (2006) · Neurosurgery · doi:10.1227/01.neu.0000223445.22938.bd · Cited by 145
Metabolic effects of prolactin
Pirchio, R., Graziadio, C., Colao, A., Pivonello, R., & Auriemma, R. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1015520 · Cited by 139
Self-citationEffectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men
Shimon, I., Benbassat, C. A., & Hadani, M. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0646 · Cited by 137
Predictors of remission of hyperprolactinaemia after long‐term withdrawal of cabergoline therapy
Colao, A., Sarno, A. D., Guerra, E., Pivonello, R., Cappabianca, P., Caranci, F., Elefante, A., Cavallo, L. M., Briganti, F., Cirillo, S., et al. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02905.x · Cited by 126
Self-citationDiagnosis and Treatment of Hypopituitarism
Kim, S. Y. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.4.443 · Cited by 125
Giant prolactinomas: the therapeutic approach
Moraes, A. B., Silva, C. M. D. S., Neto, L. V., & Gadelha, M. R. (2013) · Clinical Endocrinology · doi:10.1111/cen.12242 · Cited by 122
Grossman, A., Johannsson, G., Quinkler, M., & Zelissen, P. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0450 · Cited by 119
Salenave, S., Ancelle, D., Bahougne, T., Raverot, G., Kamenický, P., Bouligand, J., Guiochon‐Mantel, A., Linglart, A., Souchon, P., Nicolino, M. P., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3670 · Cited by 115
Glezer, A., & Bronstein, M. D. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.11.003 · Cited by 104
Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
Ide, V., Vanderschueren, D., & Antonio, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010021 · Cited by 101
Hyperprolactinaemia in male infertility: Clinical case scenarios
Dabbous, Z., & Atkin, S. L. (2017) · Arab Journal of Urology · doi:10.1016/j.aju.2017.10.002 · Cited by 101
Shimon, I., Sosa, E., Mendoza, V., Greenman, Y., Tirosh, A., Espinosa-Cárdenas, E., POPOVIC, V. M., Glezer, A., Bronstein, M. D., & Mercado, M. (2016) · Pituitary · doi:10.1007/s11102-016-0723-4 · Cited by 98
Growth hormone, prolactin, and sexuality
Galdiero, M., Pivonello, R., Grasso, L. F. S., Cozzolino, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/bf03345805 · Cited by 86
Self-citationUPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS
Lim, C. T., & Korbonits, M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0034 · Cited by 86
Qu, X., Wang, M., Wang, G., Han, T., Mou, C., Han, L., Jiang, M. C., Qu, Y., Zhang, M., Pang, Q., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0961 · Cited by 84
Cozzi, R. C., Ambrosio, M. R., Attanasio, R., Battista, C., Bozzao, A., Caputo, M., CICCARELLI, E., Marinis, L. D., Menis, E. D., Fustini, M. F., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0977 · Cited by 77
De Rosa, M., Ciccarelli, A., Zarrilli, S., Guerra, E., Gaccione, M., Di Sarno, A., Lombardi, G., & Colao, A. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02461.x · Cited by 76
Self-citationDrug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women
Colao, A. A. L., Sarno, A. D., Guerra, E., Leo, M. D., Mentone, A., & Lombardi, G. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0160 · Cited by 76
Self-citationAzoospermia due to Spermatogenic Failure
Berookhim, B. M., & Schlegel, P. N. (2013) · Urologic Clinics of North America · doi:10.1016/j.ucl.2013.08.004 · Cited by 74
Headache and pituitary disease: a systematic review
Kreitschmann‐Andermahr, I., Siegel, S., Carneiro, R. W., Maubach, J., Harbeck, B., & Brabant, G. E. (2013) · Clinical Endocrinology · doi:10.1111/cen.12314 · Cited by 74
The risks of overlooking the diagnosis of secreting pituitary adenomas
Brue, T. C., & Castinetti, F. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0516-x · Cited by 75
PRL Secreting Adenomas in Male Patients
Ciccarelli, A., Guerra, E., Rosa, M. D., Milone, F., Zarrilli, S., Lombardi, G., & Colao, A. A. L. (2005) · Pituitary · doi:10.1007/s11102-005-5084-3 · Cited by 73
Self-citationMale infertility: a critical review of pharmacologic management
Hamada, A., Montgomery, B. D., & Agarwal, A. K. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.740011 · Cited by 71
Clinical Reproductive Medicine and Surgery: A Practical Guide
Falcone, T., & Hurd, W. W. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6837-0 · Cited by 71
Diagnosis and Treatment of Hypopituitarism: An Update
van Aken, M. O., & Lamberts, S. W. J. (2005) · Pituitary · doi:10.1007/s11102-006-6039-z · Cited by 72
Treatment of Pituitary Tumors: Dopamine Agonists
Iván, G., Szigeti-Csúcs, N., Oláh, M., Nagy, G. M., & Góth, M. (2005) · Endocrine · doi:10.1385/endo:28:1:101 · Cited by 69
Macroprolactinoma: a diagnostic and therapeutic update
Iglesias, P., & Díez, J. J. (2013) · QJM · doi:10.1093/qjmed/hcs240 · Cited by 68
Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas
Auriemma, R. S., Alcubierre, D. D., Pirchio, R., Pivonello, R., & Colao, A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00327 · Cited by 67
Self-citationSousa, S. M. C. D., Chapman, I. M., Falhammar, H., & Torpy, D. J. (2016) · Endocrine · doi:10.1007/s12020-016-1088-1 · Cited by 66
Prolactinomas in males: any differences?
Duskin‐Bitan, H., & Shimon, I. (2019) · Pituitary · doi:10.1007/s11102-019-01009-y · Cited by 64
Prolactinomas in Children and Adolescents
Colao, A. A. L., & Loche, S. (2009) · Endocrine development · doi:10.1159/000262536 · Cited by 64
Self-citationThe effects of hyperprolactinemia and its control on metabolic diseases
Auriemma, R. S., Alcubierre, D. D., Pirchio, R., Pivonello, R., & Colao, A. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1434412 · Cited by 62
Self-citationAuriemma, R. S., Galdiero, M., Vitale, P., Granieri, L., Calzo, F. L., Salzano, C., Ferreri, L., Pivonello, C., Cariati, F., Coppola, G., et al. (2015) · Neuroendocrinology · doi:10.1159/000371851 · Cited by 60
Self-citationPediatric prolactinoma: initial presentation, treatment, and long-term prognosis
Hoffmann, A., Adelmann, S., Lohle, K., Claviez, A., & Muller, H. L. (2017) · European Journal of Pediatrics · doi:10.1007/s00431-017-3042-5 · Cited by 59
Delgrange, E., Duprez, T. P. J., & Maiter, D. M. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02493.x · Cited by 58
Efficacy and Safety of Cabergoline as First Line Treatment for Invasive Giant Prolactinoma
Cho, E.-H., Lee, S. A., Chung, J. Y., Koh, E. H., Cho, Y. H., Kim, J. H., Kim, C. J., & Kim, M. (2009) · Journal of Korean Medical Science · doi:10.3346/jkms.2009.24.5.874 · Cited by 57
Hypopituitarism patterns and prevalence among men with macroprolactinomas
Tirosh, A., Benbassat, C. A., Lifshitz, A., & Shimon, I. (2014) · Pituitary · doi:10.1007/s11102-014-0563-z · Cited by 54
Women with prolactinomas presented at the postmenopausal period
Shimon, I., Bronstein, M. D., Shapiro, J., Tsvetov, G., Benbassat, C. A., & Barkan, A. L. (2014) · Endocrine · doi:10.1007/s12020-014-0259-1 · Cited by 53
Long-term Efficacy of Bromocriptine in Macroprolactinomas and Giant prolactinomas in Men
Chattopadhyay, A., Bhansali, A., & Masoodi, S. R. (2005) · Pituitary · doi:10.1007/s11102-005-5111-4 · Cited by 51
Diagnosis and treatment of infertility-related male hormonal dysfunction
Kathrins, M. N., & NIEDERBERGER, C. S. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.62 · Cited by 51
Lin, S., Zhang, A., Zhang, X., & Wu, Z. B. (2019) · Neuroendocrinology · doi:10.1159/000504000 · Cited by 49
Management of resistant prolactinomas
Olafsdottir, A., & Schlechte, J. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0290 · Cited by 49
Prolactin in men's health and disease
Bolyakov, A., & Paduch, D. A. (2011) · Current Opinion in Urology · doi:10.1097/mou.0b013e32834bdf01 · Cited by 44
Unveiling the Role of Prolactin and its Receptor in Male Reproduction
Raut, S., Deshpande, S., & Balasinor, N. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0859-1144 · Cited by 48
Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
Karavitaki, N., Dobrescu, R., Byrne, J. V., Grossman, A. B., & Wass, J. A. H. (2013) · Clinical Endocrinology · doi:10.1111/cen.12124 · Cited by 47
Ribeiro, R. S., & Abucham, J. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0084 · Cited by 47
Diagnosis and treatment of pituitary tumors
Kreutzer, J., & Fahlbusch, R. (2004) · Current Opinion in Neurology · doi:10.1097/00019052-200412000-00009 · Cited by 46
Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome
Iglesias, P., Bernal, C., Villabona, C. M., Castro, J. C., Arrieta, F., & Díez, J. J. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04351.x · Cited by 46
Prolactinomas diagnosed in the postmenopausal period: Clinical phenotype and outcomes
Santharam, S., Tampourlou, M., Arlt, W., Ayuk, J., Gittoes, N. J. L., Toogood, A. A., Webster, R., & Karavitaki, N. (2017) · Clinical Endocrinology · doi:10.1111/cen.13399 · Cited by 45
Do nothing but observe microprolactinomas: when and how to replace sex hormones?
Bonert, V. S. (2020) · Pituitary · doi:10.1007/s11102-020-01039-x · Cited by 44
The Role of Dopamine Agonists in Pituitary Adenomas
Giraldi, E. A., & Ioachimescu, A. G. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.05.006 · Cited by 38
Prolactin in headache and migraine: A systematic review of clinical studies
Al‐Karagholi, M. A., Kalatharan, V., Ghanizada, H., Gram, C., Dussor, G. O., & Ashina, M. (2023) · Cephalalgia · doi:10.1177/03331024221136286 · Cited by 41
MANAGEMENT OF ENDOCRINE DISEASE: Visual morbidity in patients with pituitary adenoma
Lithgow, K. C., Batra, R., Matthews, T., & Karavitaki, N. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0349 · Cited by 40
Eroukhmanoff, J., Téjédor, I., Potorac, I., Cuny, T., Bonneville, J., Dufour, H., Weryha, G., Beckers, A. M., Touraine, P. A., Brue, T. C., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0897 · Cited by 39
Melmed, S. K., & Kleinberg, D. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00009-5 · Cited by 39
Działach, Ł., Sobolewska, J., Żak, Z., Respondek, W., & Witek, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1338345 · Cited by 39
Day, P., Glerean, M., Lovazzano, S., Pietrani, M. A., Christiansen, S. B., Balzaretti, M., Kozak, A., & Carrizo, A. G. (2010) · Frontiers of hormone research · doi:10.1159/000318494 · Cited by 38
Cardiometabolic profile of young women with hypoprolactinemia
Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2022) · Endocrine · doi:10.1007/s12020-022-03145-1 · Cited by 37
Overview of Hyperprolactinemia: General Approach and Reproductive Health Implications
Haidenberg-David, F., Sidauy-Adissi, J., Moscona-Nissan, A., Jonguitud-Zumaya, E., Fugarolas-Morinelli, M., Martínez-Mendoza, F., Taniguchi‐Ponciano, K., Marrero–Rodríguez, D., & Mercado, M. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103102 · Cited by 37
LeBaron, M. J., Ahonen, T. J., Nevalainen, M. T., & Rui, H. (2006) · Endocrinology · doi:10.1210/en.2006-1219 · Cited by 36
Rastogi, A., Bhansali, A. K., Dutta, P. R., Singh, P., Vijaivergiya, R., Gupta, V., Sachdeva, N. K., Bhadada, S. K., & Walia, R. (2013) · Clinical Endocrinology · doi:10.1111/cen.12149 · Cited by 34
New horizons in testosterone and the ageing male
Ahern, T., & Wu, F. C. W. (2015) · Age and Ageing · doi:10.1093/ageing/afv007 · Cited by 34
Male prolactinomas presenting with normal testosterone levels
Shimon, I., & Benbassat, C. A. (2013) · Pituitary · doi:10.1007/s11102-013-0497-x · Cited by 34
Management of Male Fertility in Hypogonadal Patients on Testosterone Replacement Therapy
Fink, J. E., Ide, H., & Horie, S. (2024) · Medicina · doi:10.3390/medicina60020275 · Cited by 33
Tirosh, A., Benbassat, C. A., & Shimon, I. (2015) · Endocrine Practice · doi:10.4158/ep15804.or · Cited by 33
Management of macroprolactinomas
Tirosh, A., & Shimon, I. (2015) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-015-0006-4 · Cited by 33
Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists
Kars, M., Pereira, A. M., Smit, J. W. A., & Romijn, J. A. (2008) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2008.11.012 · Cited by 32
Prolactin and reproductive medicine
Davis, J. R. (2004) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/01.gco.0000136500.87452.b0 · Cited by 32
Prolactin in Human Reproduction
Molitch, M. E. (2009) · Yen & Jaffe's Reproductive Endocrinology · doi:10.1016/b978-1-4160-4907-4.00003-6 · Cited by 31
Body fat in men with prolactinoma
Naliato, E. C. O., Violante, A., Gaccione, M., Caldas, D., Filho, A. L., Loureiro, C. R., Fontes, R. G., Schrank, Y., Costa, F. S. R., & Colao, A. A. L. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345636 · Cited by 31
Self-citationGiant prolactinomas: clinical manifestations and outcomes of 16 Arab cases
Almalki, M., Buhary, B. M., ALZAHRANI, S. H., Alshahrani, F., Alsherbeni, S., Alhowsawi, G., & Aljohani, N. (2014) · Pituitary · doi:10.1007/s11102-014-0588-3 · Cited by 30
Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment
Shimon, I. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102883 · Cited by 30
Quality of life in Prolactinoma: A systematic review
Castle‐Kirszbaum, M., Biermasz, N. R., Kam, J. K. T., & Goldschlager, T. (2024) · Pituitary · doi:10.1007/s11102-024-01392-1 · Cited by 30
Wiser, H. J., Sandlow, J. I., & Köhler, T. S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3335-4_1 · Cited by 30
Arduç, A., Gökay, F., Isik, S., Özuğuz, U., Akbaba, G., Tütüncü, Y., Berker, D. S., Kucukler, F. K., Aydın, Y., & Guler, S. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0212-4 · Cited by 28
Shimon, I., Benbassat, C. A., Tzvetov, G., & Grozinsky‐Glasberg, S. (2010) · Pituitary · doi:10.1007/s11102-010-0251-6 · Cited by 28
Clinical Presentation and Management of Headache in Pituitary Tumors
Suri, H., & Dougherty, C. O. (2018) · Current Pain and Headache Reports · doi:10.1007/s11916-018-0710-8 · Cited by 28
Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis
Yagnik, K. J., Erickson, D. Z., Bancos, I., Atkinson, J. L. D., Choby, G. W., Peris‐Celda, M., & Gompel, J. J. V. (2021) · Pituitary · doi:10.1007/s11102-021-01188-7 · Cited by 28
Disorders of Prolactin Secretion and Prolactinomas
Bronstein, M. D. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00018-6 · Cited by 26
Italian Guidelines for the Management of Prolactinomas
Cozzi, R. C., Auriemma, R. S., Menis, E. D., Esposito, F., Ferrante, E., Iatì, G., Mazzatenta, D., Poggi, M., Rudà, R., Tortora, F., et al. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230511104045 · Cited by 25
Self-citationNaves, L. A., Jaffrain‐Rea, M., Vencio, S. A. C., Jacomini, C. Z., Casulari, L. A., Daly, A., & Beckers, A. M. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000800017 · Cited by 25
Yang, A., Cho, S. Y., Park, H., Kim, M. S., Kong, D., Shin, H.-J., & Jin, D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00527 · Cited by 24
Sexual Dysfunction in Men and Women
Bhasin, S., & Basson, R. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00020-1 · Cited by 24
Current and Emerging Medical Therapies in Pituitary Tumors
Sahakian, N., Castinetti, F., Brue, T. C., & Cuny, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040955 · Cited by 22
Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma
Rudman, Y., Duskin‐Bitan, H., Masri‐Iraqi, H., Akirov, A., & Shimon, I. (2022) · Pituitary · doi:10.1007/s11102-022-01259-3 · Cited by 22
Glezer, A., & Bronstein, M. D. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000002961 · Cited by 22
Chanson, P., & Maiter, D. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00016-7 · Cited by 27
Giant prolactinoma: case report and review of literature
Rahmanian, M., Meybodi, H. A., Larijani, B. A., & Mohajeri‐Tehrani, M. R. (2013) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-12-3 · Cited by 21
Metadata
- Authors
- Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., & Lombardi, G.
- Affiliations
- Federico II University Hospital (IT)
- Corresponding author
- Colao, Annamaria
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-04
- Volume
- 89
- Issue
- 4
- Pages
- 1704-1711
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2091047975
- Semantic Scholar
- 1e7fe5139d0e093e73f435b5c99704ece8f0a0ef
- Cited by
- 256
- References
- 28
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 14 · 2023: 15 · 2022: 13 · 2021: 13 · 2020: 7 · 2019: 13 · 2018: 8 · 2017: 11 · 2016: 15 · 2015: 8 · 2014: 10 · 2013: 16 · 2012: 11
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- cabergoline, prolactinoma, macroprolactinoma, microprolactinoma, prolactin normalization, tumor shrinkage, pituitary function recovery, hypogonadism, testosterone, semen quality, sperm count, sperm motility, visual field defects, headache, galactorrhea, hypopituitarism, dopamine agonists
- MeSH terms
- Cabergoline, Adolescent, Adult, Aged, Drug Administration Schedule, Ergolines, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Pituitary Gland, Pituitary Neoplasms, Prolactin, Semen, Prolactinoma, Treatment Outcome, Dopamine Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.